Purpose: The aim was to assess the value of tumor lesion glycolysis (TLG) and tumor lesion proliferation (TLP) determined by FDG and 3'-deoxy-3'-18 Ffluorothymidine (FLT) PET for response prediction and prognostic differentiation in patients with advanced nonYsmall cell lung cancer (NSCLC) treated with erlotinib. Patients and Methods: FDG-PET and FLT-PET were performed in 30 patients with untreated Stage IV NSCLC before start of therapy, 1 (early) and 6 (late) weeks after erlotinib treatment. Functional tumor volume parameters including TLG in FDG-PET and TLP in FLT-PET were measured in the sum of up to 5 lesions per scan. Metabolic response was assessed using different cutoff values for percentage changes of TLG and TLP. Absolute baseline and residual levels of TLG and TLP were used for dichotomizing the patients into 2 groups. Kaplan-Meier analysis and the log-rank test were performed to analyze the association with progression-free survival (PFS). Results: Patients with a metabolic response measured by early changes of TLP and late changes of TLG and TLP showed a significantly better PFS than metabolically nonresponding patients. A lower cutoff value of 20% or 30% for definition of metabolic response showed better differentiation between metabolically responding and nonresponding patients in cases where the 45% cutoff value revealed no significant results. Furthermore, patients with lower absolute early and late residual TLG and TLP levels had a significantly prolonged PFS. In contrast, absolute baseline TLG and TLP levels showed no significant association with PFS. Conclusions: In patients with advanced NSCLC, percentage changes of TLG and TLP and absolute residual TLG and TLP levels under erlotinib treatment emerged as strong predictive factors for PFS. Our findings indicate that a cutoff value of 20% or 30% for definition of metabolic response measured by percentage changes of TLG and TLP provides suitable results for response prediction, which should be further validated.
S ince the introduction of PET for response assessment in clinical trials, various quantitative PET parameters measuring treatmentinduced functional changes have been challenged. 1 In this context, the SUV and percentage changes of SUVs during treatment are the most widely applied measures used in advanced nonYsmall cell lung cancer (NSCLC). 2Y4 The current recommendations propose the measurement of additional functional tumor volume parameters for further explorative analysis. 1 Total lesion glycolysis (TLG) in FDG-PET, 5 or the analogous total lesion proliferation (TLP) in 3'-deoxy-3'- 18 Ffluorothymidine (FLT) PET, 6 appear promising, as they combine information about the functional activity and volumetric data of the tumor. A reduction of 45% or more is proposed as the definition for metabolic response as assessed by TLG. 1 This cutoff value was considered a reasonable starting point for evaluation of response assessment using functional tumor volume parameters. Indeed, we recently showed that percentage changes of TLG and TLP might be helpful for response prediction. 7 However, the optimal cutoff value still remains to be defined. In addition to percentage changes, absolute single values could be used before treatment as a prognostic marker and during treatment as a predictive factor.
The aim of this explorative analysis was therefore to investigate the value of TLG and TLP, using different cutoff values of percentage changes and absolute single values before and during erlotinib treatment, for response prediction and prognostic differentiation.
PATIENTS AND METHODS

Patients
Data of 30 patients with confirmed advanced NSCLC, who were recruited into the trial at the University Hospital of Cologne between September 2007 and September 2009, 7 were included in the current analysis. The trial was approved by the local ethics committee, the responsible Federal Institute for Drugs and Medical Devices (BfArM), the responsible federal state authorities of North Rhine-Westphalia and the Federal Office for Radiation Protection (BfS); Clinical Trials: NCT00568841.
FDG-PET and FLT-PET were performed at baseline. In 30 patients, early FDG-PET and, in 28 patients, early FLT-PET data were available for analysis. In 22 patients, late FDG-PET and late FLT-PET data were available for additional analysis. Eight patients missed late FDG-PET and FLT-PET, and 6 of these had shown early progression before day 42. Images were acquired 59 T 14 and 58 T 15 minutes after intravenous injection of 365 T 30 of FDG and 305 T 89 MBq of FLT, respectively. The attenuation-corrected scan trajectory covered 90 cm (6 bed positions: 5-minute emission, 3-minute transmission). Scans were corrected for decay, dead time, scatter and randoms, and reconstructed by ordered subset expectation maximization using 4 iterations and 16 subsets, an image matrix size of 128 Â 128, and Gaussian post smoothing of 5 mm in full width at half maximum. With these settings, the final image spatial resolution was approximately 7 mm.
PET Quantitative Analysis
Quantitative analyses were performed with a 3-dimensional region-growing algorithm for tumor volume of interest definition for quantitative analysis. This software tool was developed in-house at the VU University Medical Center Amsterdam, The Netherlands, and makes use of the 3D search algorithm in the IDL software package version 6.2 (Interactive Data Language, Research Systems Inc., Boulder, CO). 8, 9 The following quantitative parameters were obtained in all patients: (1) SUV with the 3-dimensional isocontour at 50% of the maximum pixel value (SUV 50 ), (2) functional tumor volume (FTV) estimated on the basis of the SUV 50 isocontour, (3) and TLG for FDG-PET and TLP for FLT-PET calculated as the product of FTV and SUV 50 .
Functional tumor volume parameters were measured as the sum of up to a maximum of 5 measurable target lesions as proposed by PERCIST. 1 Wherever possible, target lesions were selected that were suitable for analysis with both tracers and for evaluation according to RECIST. 10 Percentage changes of these parameters and absolute residual values from a single PET study early and late during treatment were used for treatment response prediction and classifying responses. Absolute values of these parameters obtained from a single PET at baseline were used for prognostic differentiation.
Statistical Analysis
Statistical analysis was performed with SPSS Statistics (Version 19, IBM SPSS; IBM Corp, Ehningen, Germany). Clinical characteristics and quantitative data for the obtained SUVs were expressed as means T standard deviation (SD), unless otherwise specified. For survival analysis, patients were divided into 2 groups according to different cutoff values. For percentage changes of values, metabolic response was first defined as a reduction of 45% or greater according to the current PERCIST guidelines. To assess the predictive value of other cutoff values for percentage changes, the cutoff value was varied between 0% and 50% in 5% steps. To assess the predictive value of absolute residual values and the prognostic value of absolute baseline values, patients were divided into 2 groups according to median values for each of the parameters. As a comparison of medians did not produce any significant survival analysis results (data not shown), absolute cutoff values were varied between the 10% percentile and the median in 5% steps to find the best cutoff value with the minimum P value. Progression-free survival (PFS) was chosen as the endpoint for survival analysis. Progression-free survival was defined as the time between start of medication and death or progression under ongoing medication. Progression was defined according to RECIST in an independent radiologic review blinded to PET results. CT assessment was performed using a 16-slice multidetector CT scanner (Brilliance 16, Philips Medical Systems, The Netherlands) within 10 days before start of treatment, at 6 weeks of treatment and every 12 weeks thereafter. Progression-free survival was estimated using Kaplan-Meier analysis, and between-group differences were compared using the log-rank test. Univariate Cox regression analysis was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). For all tests, a P value of less than 0.05 was considered statistically significant.
RESULTS
Patient Characteristics
Patients' characteristics are presented in Table 1 . Table 2 summarizes the mean and range for the functional imaging parameter values obtained for baseline and early residual and late residual FDG-PET and FLT-PET.
Percentage Changes for Treatment Response Prediction
Early and Late Changes in FDG-PET and PFS
Metabolic response, as measured by early changes of TLG, was not associated with an improved PFS, regardless of the cutoff value chosen for definition of metabolic response ( Fig. 1 ). Patients with a late metabolic response (n = 5) measured with TLG and defined as a reduction of 45% or greater showed a significantly longer PFS (453 days [95% CI, 0Y1320 days] vs 133 days [95% CI, 78Y188 days]; HR, 4.45 [95% CI, 0.97Y20.52], P = 0.040) compared with metabolically nonresponding patients (n = 17) ( Fig. 1 ). Metabolic response .52], P = 0.015) compared with metabolic nonresponse (n = 11), and a better differentiation between metabolic responding and nonresponding patients was achieved (Fig. 1 ).
In the analysis, using early and late changes of FTV in FDG-PET, late metabolic response, defined as a reduction of 30%, was associated with a significantly better PFS, whereas late metabolic response, defined as a reduction of 45%, was not associated with any significant improvement in PFS. Metabolic response measured by early changes in FTV, was not associated with an improved PFS. No other clinical variable (age, sex, histology or Eastern Cooperative Oncology Group performance score) was associated with PFS.
Early and Late Changes in FLT-PET and PFS
Patients with an early metabolic response (n = 4), measured with TLP and defined as a reduction of 45% or greater showed a significantly longer PFS (133 days [95% CI, 0Y553 days] vs 55 days [95% CI, 0Y146 days]; HR, 4.23 [95% CI, 0.96Y18.55]; P = 0.039) compared with metabolically nonresponding patients (n = 24) ( Fig. 2) . More importantly, if metabolic response was defined as a reduction of 30% (n = 7) or 20% (n = 13) in TLP, patients classified as metabolic response demonstrated a longer PFS (238 days [95% CI, 97Y379 days] vs 50 days [95% CI, 40Y60 days]; HR, 2.97 [95% CI, 1.10Y8.01]; P = 0.023) and (238 days [95% CI, 149Y326 days] vs 48 days [95% CI, 46Y49 days]; HR, 5.79 [95% CI, 2.18Y15.43]; P G 0.001), respectively (Fig. 2) . Metabolic response measured by late changes of TLP and defined as a reduction of 45% was not associated with a longer PFS (Fig. 2) . In contrast, patients with a late metabolic response (n = 6), measured with TLP and defined as a reduction of 30% or greater, showed a significantly longer PFS (183 days [95% CI, 0Y567 days] vs 105 days [95% CI, 58Y152 days]; HR, 3.71 [95% CI, 1.05Y13.15]; P = 0.031) in comparison to metabolically nonresponding patients (n = 16) (Fig. 2) .
In the analysis, using early and late changes of FTV in FLT-PET, early metabolic response also identified a group of patients with significantly better PFS, independent of the cutoff value for definition of 
Absolute Residual Values During Treatment as a Predictive Factor
Early and Late Residual TLG Values in FDG-PET Significant differences in PFS were observed when patients were divided into 2 subgroups according to early and late residual TLG in FDG-PET ( Fig. 3) . Patients (n = 7) with a lower early residual TLG (e47) showed a significantly prolonged PFS (216 days [95% CI, 160Y272 days] vs 50 days [95% CI, 0Y128 days]; HR, 3.31 [95% CI, 1.22Y8.97]; P = 0.012) than patients (n = 23) with a higher TLG (947.00). Likewise, patients (n = 5) with a lower late residual TLG (e39.00) demonstrated a significantly prolonged PFS (216 days [95% CI, 145Y287 days] vs 105 days [95% CI, 11Y199 days]; HR, 3.38 [95% CI, 0.97Y11.78]; P = 0.043) than patients (n = 17) with a higher TLG (939).
Early and Late Residual TLP Values in FLT-PET
Significant differences in PFS were observed when patients were divided into 2 subgroups according to early and late residual TLP in FLT-PET ( Fig. 3 ). Patients (n = 5) with a lower early residual TLP (G = 18) showed a significantly prolonged PFS (216 days [95% CI, 145Y287 days] vs 98 days [95% CI, 17Y179 days]; HR, 3.48 [95% CI, 1.02Y11.88]; P = 0.034) than patients (n = 23) with a higher TLP (918.00). Patients (n = 7) with a lower late residual TLP (e20.00) showed a significantly prolonged PFS (216 days [95% CI, 160Y272 days] vs 105 days [95% CI, 17Y193 days]; HR, 3.65 [95% CI, 1.17Y11.33]; P = 0.018) than patients (n = 15) with a higher TLP (920.00).
Early and Late Residual FTV Values Measured in FDG-PET and FLT-PET
Significant differences in PFS were observed only when patients were divided into 2 subgroups according to early residual FTV in FLT-PET and late residual FTV in FDG-PET. Patients (n = 16) with a lower early residual FTV (e19) in FLT-PET showed a significantly prolonged PFS (183 days [95% CI, 1Y265 days] vs 48 days [95% CI, 46Y50 days]; HR, 2.43 [95% CI, 1.08Y5.47]; P = 0.026) than patients (n = 12) with a higher FTV (919.00). Patients (n = 10) with a lower late residual FTV (e30) in FDG-PET showed a significantly better PFS (194 days [95% CI, 143Y245 days] vs 105 days [95% CI, 59Y151 days]; HR 3.00 [95% CI, 1.09Y8.25]; P = 0.026) than patients (n = 12) with a higher FTV (930). No significant differences in PFS were observed when patients were divided into 2 groups according to early FTV in FDG-PET and late FTV in FLT-PET.
Absolute Baseline Values as a Prognostic Factor
No significant differences in PFS were observed when patients were divided into 2 groups according to baseline TLG, TLP, and FTV values in FDG-PET and FLT-PET. 
DISCUSSION
The current analysis of the results for the functional tumor volume parameters TLG and TLP, derived from FDG-PET and FLT-PET in up to 5 lesions in a total of 30 patients before, early (1 week), and late (6 weeks) during first-line erlotinib treatment demonstrates the following:
1. Metabolic response measured by percentage changes in TLG and TLP was associated with an improved survival. Furthermore, a cutoff value of 20% or 30% for definition of metabolic response based on percentage changes in TLG and TLP provided suitable results for response prediction. 2. Absolute residual TLG and TLP levels measured early or late in the course of erlotinib treatment constitute a strong predictive factor for PFS among patients with advanced NSCLC treated with erlotinib. 3. The prognostic impact of absolute TLG and TLP levels at baseline is limited.
Morphological and Functional Tumor Volume for Response Assessment
To date, tumor size measurement with CTaccording to RECIST is the standard for response evaluation. 10 However, the use of tumor volume based on CT measurement is limited for several reasons. First, tumor volume derived from CT does not always represent the real tumor burden, as a tumor mass can be heterogeneous with, for instance, hypoxic or necrotic regions. Second, treatment response is not always associated with relevant tumor shrinkage, as treatment might induce tumor necrosis or edema. Here, the development of functional tumor volume parameters, especially TLG and TLP is recognized as potentially important for studying the behavior of the whole tumor. 5, 6 Larson et al 5 introduced TLG as a quantitative measure combining entire tumor burden glycolysis and volumetric data to evaluate treatment-induced changes in the entire tumor mass. tumor lesion proliferation describes the entire proliferative volume of a tumor and its proliferation intensity. 6 Despite promising preliminary results, the question remains how and to what extent these parameters could help to predict response to treatment or provide prognostic information. 1
Percentage Changes in TLG and TLP for Response Prediction
Percentage changes in quantitative PET parameters are commonly considered for response prediction. 1Y4 For TLG, metabolic response is defined as a reduction of 45% or more according to the current PERCIST guidelines. 1 This cutoff value was based on the assumption that more pronounced changes are necessary to constitute a significant response in terms of TLG levels than are required for SUV parameters. However, it is still unknown what reduction in TLG is necessary for a metabolic response. The recommendation of a 45% cutoff value was therefore seen as a useful starting point for further explorative analysis. Indeed, we recently observed that percentage changes of TLG and TLP, measured according to PERCIST, might be helpful for response prediction. 7 Nevertheless, the predictive value was limited, as neither those patients with an early metabolic response measured by TLG nor those with a late metabolic response measured by TLP showed a prolonged PFS. 7 Here, we observed that in cases where use of the 45% cutoff value did not reveal any significant results in differentiating metabolic response and metabolic nonresponse, a lower cutoff value for definition of metabolic response for TLG and TLP achieved better results. In these cases, patients with a metabolic response defined as a reduction of 20% or 30% demonstrated a better PFS than patients classified as metabolic response according to the 45% cutoff value provided by PERCIST. This indicates that lower cutoff values for definition of metabolic response for TLG/TLP might be suitable for response prediction. As 8 patients missed late PET, the comparability of the predictive value of early and late PET is limited. That 6 of these 8 patients had shown early progression may have additionally affected the ability of late PET to differentiate metabolic responding and nonresponding patients.
Residual TLG and TLP for Response Prediction
In addition to the measurement of percentage changes, it is reasonable to assume that the absolute residual TLG and TLP value, that is, the TLG/TLP from a single scan during treatment, could be of predictive value. 11 Indeed, we were able to show that early and late residual TLG and TLP were strong predictive factors for PFS in patients with advanced NSCLC treated with erlotinib. However, the use of residual TLG or TLP for response prediction is limited, as several technical, physical and biological factors affect absolute quantitative PET parameters. 11 Additionally, separate cutoff values may need to be validated for each cancer entity, each therapeutic regimen and each quantitative parameter. Residual TLG and TLP values during treatment could therefore be of particular relevance in cases where determination of percentage changes is hindered, for example, where no baseline PET scan was performed or the baseline PET scan was performed on another PET scanner with different reconstruction settings.
Baseline TLG and TLP as Prognostic Factors
Baseline quantitative PET parameters can be used as prognostic factors. For functional tumor volume parameters, Liao et al 12 recently observed that TLG had a high prognostic value in 169 NSCLC patients who underwent FDG-PET before chemotherapy. Similar findings were seen in other tumor entities: Gulec et al 13 analyzed 20 patients with colorectal cancer and reported a significant association of baseline TLG with survival. Furthermore, TLG was found to be a significant prognostic factor for overall survival in patients with esophageal cancer 14, 15 as well as in patients with osteosarcoma. 16 However, these findings are contrary to the results presented here, as we could show no prognostic impact for TLG and TLP in our patient cohort. Possible explanations might be the heterogeneous tumor entities and different treatment regimens after the baseline scan, which makes the results hard to compare.
Standardization for TLG and TLP
Methods for determining functional tumor volume parameters in PET imaging are currently evolving and not yet fully standardized. 6,17Y19 Several definitions of TLG and TLP with varying SUVs and FTVs have been proposed without a clear recommendation for standardized calculation. Recently, two studies investigated the repeatability and reproducibility of functional tumor volume measurements and different tumor delineation methods in FDG-PET and FLT-PET. 6, 19 The results indicated that an accurate determination could be achieved by appropriate standardization. In a recent study, Frings et al 20 investigated the test-retest variability of functional tumor volume measurements, confirming an accurate FTV determination with a threshold value close to 50% in lung cancer. A low test-retest variability, as reported by Frings et al, is of particular importance for monitoring treatment response. Here, we observed that functional tumor volume parameters are indeed suitable for response assessment in a clinical setting. However, the SUV max , which is the voxel with the maximum uptake, is still considered the standard parameter for quantitative PET assessment. In the current study, we could not show any superiority of TLG and TLP over our previous results where SUV max was used to monitor treatment response. 7 We would therefore recommend keeping SUV max as the standard parameter for PET response assessment but using functional tumor volume measurements for further evaluation. As the standardization of functional volume parameters is still ongoing, further studies with larger numbers of patients will be needed to analyze their prognostic and predictive value.
